Marco Mineo

Dr. Marco Mineo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2020 in Molecular Cell
Verified
Journal Article
Closed access
MMMarco Mineo
Marco Mineo
SLShawn M. Lyons
Shawn M. Lyons
MZMykola Zdioruk
Mykola Zdioruk
NSNiklas von Spreckelsen
Niklas von Spreckelsen
RFRuben Ferrer-Luna
Ruben Ferrer-Luna
ACAntonio Chiocca
Antonio Chiocca

13 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JTJoseph Toker
Joseph Toker
JIJ. Bryan Iorgulescu
J. Bryan Iorgulescu
ALAlexander L. Ling
Alexander L. Ling
GVGenaro Rodriguez Villa
Genaro Rodriguez Villa
JGJosephina A.M.A. Gadet
Josephina A.M.A. Gadet
MMMarco Mineo
Marco Mineo
Purpose: mAbs targeting the PD-1/PD-L1 immune checkpoint are powerful tools to improve the survival of patients with cancer. Understanding the molecular basis of clinical response to these treatments is critical to identify patients who can benefit from this immunotherapy. In this study, we investigated long noncoding RNA (lncRNA) expression in patients with cancer treated with anti-PD-1/PD-L1 immunotherapy. Experimental Design: lncRNA expression profile was analyzed in one cohort of patients with melanoma and two independent cohorts of patients with glioblastoma (GBM) undergoing anti-PD-1/PD-L1 immunotherapy. Single-cell RNA-sequencing analyses were performed to evaluate lncRNA expression in tumor cells and tumor-infiltrating immune cells. Results: We identified the lncRNA NEAT1 as commonly upregulated between patients with melanoma with complete therapeutic response and patients with GBM with longer survival following anti-PD-1/PD-L1 treatment. Gene set enrichment analyses revealed that NEAT1 expression was strongly associated with the IFNγ pathways, along with downregulation of cell-cycle-related genes. Single-cell RNA-sequencing analyses revealed NEAT1 expression across multiple cell types within the GBM microenvironment, including tumor cells, macrophages, and T cells. High NEAT1 expression levels in tumor cells correlated with increased infiltrating macrophages and microglia. In these tumor-infiltrating myeloid cells, we found that NEAT1 expression was linked to enrichment in TNFα/NFκB signaling pathway genes. Silencing NEAT1 suppressed M1 macrophage polarization and reduced the expression of TNFα and other inflammatory cytokines. Conclusions: These findings suggest an association between NEAT1 expression and patient response to anti-PD-1/PD-L1 therapy in melanoma and GBM and have important implications for the role of lncRNAs in the tumor microenvironment.

4 March 2025 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
SSShikha Saini
Shikha Saini
JGJosephina A. M. A. Gadet
Josephina A. M. A. Gadet
GFGordon J. Freeman
Gordon J. Freeman
ECE. Antonio Chiocca
E. Antonio Chiocca
MMMarco Mineo
Marco Mineo
Purpose: The potent antitumor effects of interleukin 12 (IL12) gene therapy in glioblastoma (GBM) are significantly attenuated by the highly immunosuppressive microenvironment and the upregulation of the PD-1/PD-L1 immune checkpoint. However, combining IL12 gene therapy with PD-1/PD-L1 inhibitors failed to improve efficacy. This study aims to assess the effects of silencing the immunosuppressive long noncoding RNA INCR1 when combined with IL12 therapy. Methods: RNAscope in situ hybridization was performed to analyze INCR1 and PD-L1 expression in tumor tissues from GBM patients pre- and post-IL12 gene therapy. Quantitative PCR was used to analyze immunosuppressive gene expression in patient-derived GBM cells co-cultured with immune cells stimulated with IL12. The effects of INCR1 and PD-L1 silencing on the expression of immunosuppressive genes were evaluated by RNA sequencing. 3D-cytotoxicity assays were performed to assess the activity of immune cells against GBM tumor cells. Results: INCR1 and PD-L1 expression was upregulated in tumor tissue from GBM patients treated with IL12 gene therapy compared to the tumor tissue of the same patients before the IL12 treatment. Co-culture of patient-derived GBM cells with IL12-stimulated immune cells increased the expression of several immunosuppressive genes. Knocking down INCR1 was more effective than silencing PD-L1 in reducing the expression of multiple immunosuppressive genes. INCR1 silencing improved IL12-mediated immune cell antitumor activity compared to monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint signaling. Conclusion: INCR1 silencing affects more immune evasive pathways than PD-L1. Targeting INCR1 may represent a valid approach to improve the efficacy of IL12 therapy in GBM.

24 March 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
GVGenaro Rodriguez Villa
Genaro Rodriguez Villa
PAPaolo Alimonti
Paolo Alimonti
JTJoseph S. Toker
Joseph S. Toker
RPRaziye Piranlioglu
Raziye Piranlioglu
MKMikayla A. Karkoski
Mikayla A. Karkoski
MMMarco Mineo
Marco Mineo
Although glioblastoma (GBM) harbors multiple genetic abnormalities leading to cell cycle deregulation, a functional mitotic checkpoint is essential to prevent mitotic catastrophe and tumor cell death. Here, we identify the RNA-binding protein HNRNPH1 as a key post-transcriptional modulator of G2/M checkpoint-associated genes in GBM. HNRNPH1 is overexpressed in malignant cells, especially in the neural- and oligodendrocyte-progenitor-like state, and its expression levels are higher in non-hypoxic regions of the tumor. Knocking out HNRNPH1 causes aberrant splicing and downregulation of several genes involved in cell division. These molecular alterations are associated with G2/M cell cycle arrest, reduced cell proliferation, abnormal cell morphology, and increased nuclear fragmentation. Silencing HNRNPH1 in vivo inhibits the tumor growth of patient-derived GBM cell-originated intracranial xenografts and has significant survival benefits. Together, our results show the critical importance of HNRNPH1 in cell cycle progression and tumor growth, potentially impacting the development of novel strategies to treat GBM.

16 September 2024
Verified
Other
Open access
PDF file
JTJoseph Toker
Joseph Toker
JIJ. Bryan Iorgulescu
J. Bryan Iorgulescu
ALAlexander L. Ling
Alexander L. Ling
GVGenaro Rodriguez Villa
Genaro Rodriguez Villa
JGJosephina A.M.A. Gadet
Josephina A.M.A. Gadet
MMMarco Mineo
Marco Mineo
Supplementary Fig. 1 Analysis of lncRNAs associated with patient response to ICB.

16 September 2024
Verified
Other
Open access
PDF file
JTJoseph Toker
Joseph Toker
JIJ. Bryan Iorgulescu
J. Bryan Iorgulescu
ALAlexander L. Ling
Alexander L. Ling
GVGenaro Rodriguez Villa
Genaro Rodriguez Villa
JGJosephina A.M.A. Gadet
Josephina A.M.A. Gadet
MMMarco Mineo
Marco Mineo
Supplementary Fig. 3 NEAT1 levels are associated with the upregulation of the interferon-gamma pathway in glioblastoma.